| scholarly article | Q13442814 |
| P50 | author | Stefan Rose-John | Q47812749 |
| Simon Jones | Q61165367 | ||
| P2093 | author name string | Georg H Waetzig | |
| Björn Rabe | |||
| Jürgen Scheller | |||
| Anwen S Williams | |||
| Athena Chalaris | |||
| Dirk Seegert | |||
| Ulrike May | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammation | Q101991 |
| P304 | page(s) | 1021-1028 | |
| P577 | publication date | 2007-11-07 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Transgenic blockade of interleukin 6 transsignaling abrogates inflammation | |
| P478 | volume | 111 |
| Q46445845 | A panel of four cytokines predicts the prognosis of patients with malignant gliomas |
| Q40912652 | ADAM17 controls IL-6 signaling by cleavage of the murine IL-6Rα from the cell surface of leukocytes during inflammatory responses |
| Q52689175 | ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling. |
| Q51556504 | Activated Schwann cells in pancreatic cancer are linked to analgesia via suppression of spinal astroglia and microglia. |
| Q47812001 | An inhibitor of interleukin-6 trans-signalling, sgp130, contributes to impaired acute phase response in human chronic liver disease |
| Q38958166 | Anti-interleukin-6 therapy through application of a monogenic protein inhibitor via gene delivery |
| Q91690142 | Blocking interleukin-6 trans-signaling protects against renal fibrosis by suppressing STAT3 activation |
| Q41550296 | Cancer-associated mutations in the canonical cleavage site do not influence CD99 shedding by the metalloprotease meprin β but alter cell migration in vitro |
| Q35928265 | Chronic inflammation in cancer development. |
| Q39326946 | Circulating Soluble IL-6R but Not ADAM17 Activation Drives Mononuclear Cell Migration in Tissue Inflammation |
| Q30318502 | Contribution of vascular cell-derived cytokines to innate and inflammatory pathways in atherogenesis |
| Q58782375 | Control of Listeria monocytogenes infection requires classical IL-6 signaling in myeloid cells |
| Q36390177 | Cutting edge: IL-6 is a marker of inflammation with no direct role in inflammasome-mediated mouse models |
| Q34116480 | Deletion of interleukin-6 in mice with the dominant negative form of transforming growth factor beta receptor II improves colitis but exacerbates autoimmune cholangitis |
| Q50097629 | Dissecting Interleukin-6 Classic- and Trans-Signaling in Inflammation and Cancer |
| Q36936364 | Epigallocatechin-3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 production. |
| Q30361595 | From cytokine to myokine: the emerging role of interleukin-6 in metabolic regulation. |
| Q26738992 | Generation of Soluble Interleukin-11 and Interleukin-6 Receptors: A Crucial Function for Proteases during Inflammation |
| Q38765969 | Genetic evidence for an essential role of neuronally expressed IL-6 signal transducer gp130 in the induction and maintenance of experimentally induced mechanical hypersensitivity in vivo and in vitro. |
| Q64060622 | Heme oxygenase-1-Dependent anti-inflammatory effects of atorvastatin in zymosan-injected subcutaneous air pouch in mice |
| Q47408388 | High Expression of STAT3 in Subcutaneous Adipose Tissue Associates with Cardiovascular Risk in Women with Rheumatoid Arthritis |
| Q37983123 | Hitting a complex target: an update on interleukin-6 trans-signalling |
| Q33706389 | IL-6 and MYC collaborate in plasma cell tumor formation in mice |
| Q33806982 | IL-6 and high glucose synergistically upregulate MMP-1 expression by U937 mononuclear phagocytes via ERK1/2 and JNK pathways and c-Jun |
| Q92686848 | IL-6 exhibits both cis- and trans-signaling in osteocytes and osteoblasts, but only trans-signaling promotes bone formation and osteoclastogenesis |
| Q34025142 | IL-6 in diabetes and cardiovascular complications. |
| Q26766606 | IL-6 pathway in the liver: From physiopathology to therapy |
| Q51369659 | IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice. |
| Q36638151 | IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality |
| Q38058509 | IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. |
| Q37949664 | IL-6/IL-6 receptor system and its role in physiological and pathological conditions |
| Q91691068 | IL-6: a cytokine at the crossroads of autoimmunity |
| Q37004125 | Identification of STOML2 as a putative novel asthma risk gene associated with IL6R. |
| Q34387624 | Impact of interleukin-6 in hematological malignancies |
| Q35054706 | Increased CD40+ Fibrocytes in Patients With Idiopathic Orbital Inflammation. |
| Q37853049 | Increased inflammation and impaired resistance to Chlamydophila pneumoniae infection in Dusp1(-/-) mice: critical role of IL-6. |
| Q28083759 | Inflammation induced loss of skeletal muscle |
| Q37676036 | Inhibition of IL-6 family cytokines by SOCS3. |
| Q39459586 | Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor |
| Q91625683 | Inhibition of interleukin-6 trans-signaling prevents inflammation and endothelial barrier disruption in retinal endothelial cells |
| Q92972305 | Interleukin 6 receptor alpha expression in PMNs isolated from prematurely born neonates: decreased expression is associated with differential mTOR signaling |
| Q48179034 | Interleukin 6 trans-signaling regulates basal synaptic transmission and sensitivity to pentylenetetrazole-induced seizures in mice |
| Q34274249 | Interleukin-1β and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis |
| Q40170313 | Interleukin-6 Family Cytokines |
| Q33586501 | Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update |
| Q43965056 | Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease |
| Q88562718 | Interleukin-6: designing specific therapeutics for a complex cytokine |
| Q35158224 | Intestinal alkaline phosphatase has beneficial effects in mouse models of chronic colitis |
| Q59326168 | Is Interleukin-6 Receptor Blockade the Holy Grail for Inflammatory Diseases? |
| Q26746659 | Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis |
| Q93016940 | Machine Learning to Understand the Immune-Inflammatory Pathways in Fibromyalgia |
| Q37690147 | Meprin Metalloproteases Generate Biologically Active Soluble Interleukin-6 Receptor to Induce Trans-Signaling |
| Q47171898 | Mesenchymal Stem Cells Secretory Responses: Senescence Messaging Secretome and Immunomodulation Perspective. |
| Q34031701 | Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training |
| Q30382563 | N-linked glycosylation is essential for the stability but not the signaling function of the interleukin-6 signal transducer glycoprotein 130. |
| Q33817373 | Over-expressing the soluble gp130-Fc does not ameliorate methionine and choline deficient diet-induced non alcoholic steatohepatitis in mice. |
| Q92075830 | Paradoxical Relationship Between Glycated Hemoglobin and Longitudinal Change in Physical Functioning in Older Adults: A Prospective Cohort Study |
| Q55098015 | Pharmacological inhibition of IL-6 trans-signaling improves compromised fracture healing after severe trauma. |
| Q27027729 | Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma |
| Q55311857 | RNase H2 Loss in Murine Astrocytes Results in Cellular Defects Reminiscent of Nucleic Acid-Mediated Autoinflammation. |
| Q92058032 | Red LED Light Is Influenced by IL-6 to Promote the Migration Ability of Oral Squamous Cell Carcinoma Cell Line |
| Q39512459 | Role of IL-6 in the etiology of hyperexcitable neuropsychiatric conditions: experimental evidence and therapeutic implications. |
| Q37429079 | Roles of IL-6-gp130 Signaling in Vascular Inflammation |
| Q95276341 | SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc |
| Q26798209 | Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies |
| Q38836137 | Shedding of Endogenous Interleukin-6 Receptor (IL-6R) Is Governed by A Disintegrin and Metalloproteinase (ADAM) Proteases while a Full-length IL-6R Isoform Localizes to Circulating Microvesicles |
| Q52672721 | Silencing of CXCL12 performs a protective effect on C5b-9-induced injury in podocytes. |
| Q37798450 | Skeletal muscle cells: from local inflammatory response to active immunity. |
| Q41769215 | SorLA in Interleukin-6 Signaling and Turnover |
| Q42722712 | Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding |
| Q28073706 | Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis |
| Q57339893 | T-cell-specific deletion of gp130 renders the highly susceptible IL-10-deficient mouse resistant to intestinal nematode infection |
| Q38134113 | Targeting gp130 to prevent inflammation and promote insulin action. |
| Q98394725 | The JAK1/STAT3/SOCS3 axis in bone development, physiology, and pathology |
| Q41500559 | The Role of Proinflammatory Pathways in the Pathogenesis of Colitis-Associated Colorectal Cancer. |
| Q35678811 | The Sbi Protein Contributes to Staphylococcus aureus Inflammatory Response during Systemic Infection |
| Q40147932 | The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation |
| Q50827435 | The balance of Interleukin (IL)-6, IL-6:soluble IL-6 receptor (IL-6R) and IL-6:sIL-6R:sgp130 complexes allows simultaneous classic and trans-signaling |
| Q38175384 | The effect of inflammatory cytokines in alcoholic liver disease. |
| Q47689869 | The effects of various mixing solutions on the biocompatibility of mineral trioxide aggregate. |
| Q42085795 | The good, the bad, and the ugly of interleukin-6 signaling. |
| Q34030580 | The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. |
| Q26770548 | The role of gp130 receptor cytokines in the regulation of metabolic homeostasis |
| Q39635639 | Therapeutic Targeting of the IL-6 Trans-Signaling/Mechanistic Target of Rapamycin Complex 1 Axis in Pulmonary Emphysema. |
| Q58027335 | Trans-Signaling Is a Dominant Mechanism for the Pathogenic Actions of Interleukin-6 in the Brain |
| Q37511971 | Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells |
| Q90289043 | Treatment of type 2 diabetes with the designer cytokine IC7Fc |
| Q36505188 | Vagal nerve stimulation blocks interleukin 6-dependent synaptic hyperexcitability induced by lipopolysaccharide-induced acute stress in the rodent prefrontal cortex |
| Q37975897 | Vascular effects of glycoprotein130 ligands--part II: biomarkers and therapeutic targets |
| Q35550033 | Viral interleukin-6: role in Kaposi's sarcoma-associated herpesvirus: associated malignancies |
| Q39519472 | WNT/β-catenin pathway is modulated in asthma patients and LPS-stimulated RAW264.7 macrophage cell line |
| Q34378756 | gp130 at the nexus of inflammation, autoimmunity, and cancer |
| Q33888245 | n-3 PUFAs reduce T-helper 17 cell differentiation by decreasing responsiveness to interleukin-6 in isolated mouse splenic CD4⁺ T cells |
Search more.